Last reviewed · How we verify
Ibritumomab Tiuxetan (Zevalin)
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that binds to CD20 on B cells and delivers yttrium-90 radiation directly to tumor cells.
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that binds to CD20 on B cells and delivers yttrium-90 radiation directly to tumor cells. Used for Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma, Previously untreated follicular lymphoma (in combination with rituximab).
At a glance
| Generic name | Ibritumomab Tiuxetan (Zevalin) |
|---|---|
| Also known as | Ibritumomab, Zevalin, IDEC-Y2B8, Rituximab (Mabthera) |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Radioimmunotherapy agent; anti-CD20 monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The drug consists of a murine anti-CD20 monoclonal antibody conjugated to a chelator that carries yttrium-90, a beta-emitting radioisotope. Upon binding to CD20-expressing B lymphoma cells, the antibody delivers high-energy radiation directly to the malignant cells, causing DNA damage and cell death. This radioimmunotherapy approach combines the targeting specificity of monoclonal antibodies with the cytotoxic power of radiation.
Approved indications
- Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma
- Previously untreated follicular lymphoma (in combination with rituximab)
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
- Infusion reactions
- Fatigue
- Nausea
- Secondary malignancies
Key clinical trials
- Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma (PHASE2)
- Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma (PHASE3)
- S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma (PHASE2)
- A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan (PHASE2)
- Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation (PHASE1, PHASE2)
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (PHASE3)
- Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine (PHASE2)
- Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |